News

MedImmune, Joslin collaborate for new diabetes meds

From the Washington Business Journal:

Gaithersburg biotech MedImmune and Boston-based Joslin Diabetes Center announced plans Tuesday to work together on new drug candidates that could someday regenerate insulin cells, increase calorie-burning“brown fat” or even replicate the effects of bariatric surgery.

It’s like you can almost feel it in the air that something amazing is happening in diabetes research. At last weekend’s JDRF TypeOneNation Research Summit in Maryland, JDRF Board Chairman John Brady discussed a Janssen Research and Development Inc-JDRF effort to “intercept” Type 1 diabetes.

Not to get my hopes up, but all this effort has to lead somewhere.

Advertisements

One thought on “MedImmune, Joslin collaborate for new diabetes meds

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s